

RECEIVED
CENTRAL FAX CENTER


- 1 -

LISTING OF CLAIMS

JAN 22 2007

CLAIMS 1-28 (canceled)

29. (previously presented) A compound of formula (I),



5

wherein :

➤ R₁ and R₂, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,

10 ➤ R₃ represents halogen, alkoxy, an optionally substituted aryl group or NR'₁R'₂ wherein R'₁ and R'₂, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,

➤ R₄ represents hydrogen or NR"₁R"₂ wherein R"₁ and R"₂, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,

15 its enantiomers, diastereoisomers, tautomers and addition salts thereof with a pharmaceutically acceptable acid or base,

it being understood that :

- the term "alkyl" denotes linear or branched hydrocarbon chain having from 1 to 8 carbon atoms,

20 - the term "alkoxy" denotes alkyl-oxy wherein the alkyl chain is linear or branched and has from 1 to 8 carbon atoms,

- the term "aryl" denotes phenyl or naphthyl,

US Serial No. 10/533,697
Supplemental Response and Amendment of January 5, 2007
Servier 457 PCT

- 2 -

- the term "heterocycle" denotes a mono- or bi-cyclic system which has from 5 to 11 carbon atoms and which may contain, in addition to the nitrogen atom to which R₁R₂, R'₁R'₂ or R''₁R''₂ are bonded, one or two further hetero atoms selected from oxygen, sulphur and nitrogen, it being possible for the heterocyclic system to be substituted by one, two or three alkyl groups,


5

- the term "substituted" associated with aryl indicates that the phenyl or naphthyl group is substituted by one, two or three identical or different groups selected from halogen, alkyl, alkoxy, polyhaloalkyl and hydroxy,

10

- "polyhaloalkyl" denotes a linear or branched carbon chain having from 1 to 3 carbon atoms and from 1 to 7 halogen atoms.

30. (previously presented) A compound of Claim 29, which is represented by formula (I'),



15

31. (previously presented) A compound of Claim 29, wherein NR₁R₂ represents NH₂, di-n-propylamine or morpholine.

32. (previously presented) A compound of Claim 30, wherein NR₁R₂ represents NH₂, di-n-propylamine or morpholine.

20

33. (previously presented) A compound of Claim 29, wherein R₃ represents 3,4-dimethoxyphenyl, 3,5-dimethylmorpholine, thiomorpholine, azepine, perhydroquinoline, pyrrolidine or chlorine.

34. (previously presented) A compound of Claim 30, wherein R₃ represents 3,4-dimethoxyphenyl, 3,5-dimethylmorpholine, thiomorpholine, azepine, perhydroquinoline, pyrrolidine or chlorine.

- 3 -

35. (previously presented) A compound of Claim 29, wherein R₄ represents hydrogen, morpholine or azepine.

36. (previously presented) A compound of Claim 30, wherein R₄ represents hydrogen, morpholine or azepine.

5 37. (previously presented) A compound of Claim 29 which is selected from :

2-(dipropylamino)-8-(4-thiomorpholinyl)pyrido[3,4-d]pyrimidin-4(3H)-one,

8-(1-azocanyl)-2-(dipropylamino)pyrido[3,4-d]pyrimidin-4(3H)-one,

8-((4a α ,8a α)-octahydro-1(2H)-quinolyl)-2-(dipropylamino)pyrido[3,4-d]pyrimidin-4(3H)-one,

10 8-((4a β ,8a α)-octahydro-1(2H)-quinolyl)-2-(dipropylamino)pyrido[3,4-d]pyrimidin-4(3H)-one,

6,8-di(1-azepanyl)-2-(dipropylamino)pyrido[3,4-d]pyrimidin-4(3H)-one,

8-(1-azepanyl)-2-(dipropylamino)-6-(4-morpholinyl)pyrido[3,4-d]pyrimidin-4(3H)-one,

8-(1-azepanyl)-2,6-di(4-morpholinyl)pyrido[3,4-d]pyrimidin-4(3H)-one,

15 2-amino-8-[(3 α ,5 β)-3,5-dimethylmorpholinyl]pyrido[3,4-d]pyrimidin-4(3H)-one,

2-amino-8-[(3 α ,5 α)-3,5-dimethylmorpholinyl]pyrido[3,4-d]pyrimidin-4(3H)-one,

8-[(3 α ,5 β)-3,5-dimethylmorpholinyl]-2-(dipropylamino)pyrido[3,4-d]pyrimidin-4(3H)-one,

20 8-[(3 α ,5 α)-3,5-dimethylmorpholinyl]-2-(dipropylamino)pyrido[3,4-d]pyrimidin-4(3H)-one,

8-[(3 α ,5 α)-3,5-dimethylmorpholinyl]-2-(4-morpholinyl)pyrido[3,4-d]pyrimidin-4(3H)-one,

25 2-amino-8-(1-azepanyl)-6-(4-morpholinyl)pyrido[3,4-d]pyrimidin-4(3H)-one,

8-chloro-2-(dipropylamino)pyrido[3,4-d]pyrimidin-4(3H)-one,

2-(dipropylamino)-8-(1-pyrrolidinyl)pyrido[3,4-d]pyrimidin-4(3H)-one,

and 8-(3,4-dimethoxyphenyl)-2-(dipropylamino)pyrido[3,4-d]pyrimidin-4(3H)-one.

38. (currently amended) A method for treating a living animal body, including a human, afflicted with a condition selected from cancer, non-insulin-dependent, type II diabetes, obesity, and hyperlipidaemia, hypercholesterolaemia and cardiovascular complications

- 4 -

~~thereof, arthrosis, and arterial hypertension,~~ comprising the step of administering to the living animal body, ~~including a human,~~ an amount of a compound of Claim 29 which is effective for alleviation of the condition.

39. (canceled)

5 40. (currently amended) A method for treating a living animal body, ~~including a human,~~ afflicted with cancer, comprising the step of administering to the living animal body, ~~including a human,~~ an amount of a compound of Claim 29 which is effective for alleviation of cancer.

41. (canceled)

10 42. (canceled)

43. (new) The method of Claim 38, wherein the living animal body is a human.

44. (new) The method of Claim 40, wherein the living animal body is a human.

15

45. (new) A pharmaceutical composition, comprising as active principle an effective amount of a compound of Claim 29, together with one or more pharmaceutically acceptable excipients or vehicles.

20